Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma.

Yenugonda V, Nomura N, Kouznetsova V, Tsigelny I, Fogal V, Nurmemmedov E, Kesari S, Babic I.

J Transl Med. 2017 Oct 18;15(1):210. doi: 10.1186/s12967-017-1312-7.

2.

Correction for Fogal et al., "Mitochondrial p32 Protein Is a Critical Regulator of Tumor Metabolism via Maintenance of Oxidative Phosphorylation".

Fogal V, Richardson AD, Karmali PP, Scheffler IE, Smith JW, Ruoslahti E.

Mol Cell Biol. 2017 Jun 29;37(14). pii: e00137-17. doi: 10.1128/MCB.00137-17. Print 2017 Jul 15. No abstract available.

3.

Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction.

Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, Cho YJ, Pingle SC, Crawford JR, Piccioni DE, Kesari S.

Oncotarget. 2015 Jan 20;6(2):1157-70.

4.

In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells.

Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati IS, Fogal V, Pastorino S, Teng D, Cong X, Pingle SC, Kapoor S, Shetty K, Aggrawal A, Vali S, Abbasi T, Chien S, Kesari S.

Br J Cancer. 2014 Oct 14;111(8):1562-71. doi: 10.1038/bjc.2014.431. Epub 2014 Aug 5.

5.

Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.

Jiang P, Mukthavaram R, Chao Y, Bharati IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, Abbasi T, Vali S, Pingle SC, Makale M, Kesari S.

J Transl Med. 2014 Jan 17;12:13. doi: 10.1186/1479-5876-12-13. Erratum in: J Transl Med. 2014;12:126. Mukthavavam, Rajesh [corrected to Mukthavaram, Rajesh].

6.

High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile.

Mukthavaram R, Jiang P, Saklecha R, Simberg D, Bharati IS, Nomura N, Chao Y, Pastorino S, Pingle SC, Fogal V, Wrasidlo W, Makale M, Kesari S.

Int J Nanomedicine. 2013;8:3991-4006. doi: 10.2147/IJN.S51949. Epub 2013 Oct 21.

7.

Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4.

Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, Fogal V, Ruoslahti E, Hahn WC, Bhatia SN.

Sci Transl Med. 2012 Aug 15;4(147):147ra112. doi: 10.1126/scitranslmed.3003778.

8.

Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice.

Hamzah J, Kotamraju VR, Seo JW, Agemy L, Fogal V, Mahakian LM, Peters D, Roth L, Gagnon MK, Ferrara KW, Ruoslahti E.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7154-9. doi: 10.1073/pnas.1104540108. Epub 2011 Apr 11.

9.

The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies.

Sánchez-Martín D, Cuesta AM, Fogal V, Ruoslahti E, Alvarez-Vallina L.

J Biol Chem. 2011 Feb 18;286(7):5197-203. doi: 10.1074/jbc.M110.161927. Epub 2010 Dec 14.

10.

Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation.

Fogal V, Richardson AD, Karmali PP, Scheffler IE, Smith JW, Ruoslahti E.

Mol Cell Biol. 2010 Mar;30(6):1303-18. doi: 10.1128/MCB.01101-09. Epub 2010 Jan 25. Erratum in: Mol Cell Biol. 2017 Jun 29;37(14 ):.

11.

Cooperative nanomaterial system to sensitize, target, and treat tumors.

Park JH, von Maltzahn G, Xu MJ, Fogal V, Kotamraju VR, Ruoslahti E, Bhatia SN, Sailor MJ.

Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):981-6. doi: 10.1073/pnas.0909565107. Epub 2009 Dec 28.

12.

Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature.

Fogal V, Sugahara KN, Ruoslahti E, Christian S.

Angiogenesis. 2009;12(1):91-100. doi: 10.1007/s10456-009-9137-5. Epub 2009 Feb 19.

PMID:
19225898
13.

Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma.

Fogal V, Zhang L, Krajewski S, Ruoslahti E.

Cancer Res. 2008 Sep 1;68(17):7210-8. doi: 10.1158/0008-5472.CAN-07-6752.

14.

In vivo tumor cell targeting with "click" nanoparticles.

von Maltzahn G, Ren Y, Park JH, Min DH, Kotamraju VR, Jayakumar J, Fogal V, Sailor MJ, Ruoslahti E, Bhatia SN.

Bioconjug Chem. 2008 Aug;19(8):1570-8. doi: 10.1021/bc800077y. Epub 2008 Jul 9.

15.

Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315.

Fogal V, Hsieh JK, Royer C, Zhong S, Lu X.

EMBO J. 2005 Aug 3;24(15):2768-82. Epub 2005 Jul 21.

16.

ASPP1 and ASPP2 are new transcriptional targets of E2F.

Fogal V, Kartasheva NN, Trigiante G, Llanos S, Yap D, Vousden KH, Lu X.

Cell Death Differ. 2005 Apr;12(4):369-76.

17.

Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage.

Hsieh JK, Yap D, O'Connor DJ, Fogal V, Fallis L, Chan F, Zhong S, Lu X.

Mol Cell Biol. 2002 Jan;22(1):78-93.

18.

Regulation of p53 activity in nuclear bodies by a specific PML isoform.

Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C, Del Sal G.

EMBO J. 2000 Nov 15;19(22):6185-95.

19.

p53 is involved in the p120E4F-mediated growth arrest.

Sandy P, Gostissa M, Fogal V, Cecco LD, Szalay K, Rooney RJ, Schneider C, Del Sal G.

Oncogene. 2000 Jan 13;19(2):188-99.

20.

Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1.

Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M, Del Sal G.

EMBO J. 1999 Nov 15;18(22):6462-71.

Supplemental Content

Support Center